Ayala PharmaceuticalsÂ Inc (AYLA) Financials

$0.50

$0.00 (0.00%)

As on 27-Jan-2023 09:30EDT

Market cap

$8 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	1.73	3.51	3.71	2.33	--	--
Cost of Revenue	1.64	3.51	3.71	1.29	--	--
Gross Profit	-1.06	-3.51	--	1.05	--	--
Operating Expenses	37.63	39.22	29.78	18.76	9.04	--
Operating Profit (EBIT)	-37.54	-39.22	-29.78	-17.71	-9.04	--
Other Income	--	--	--	--	--	--
Profit before Tax	-37.77	-39.48	-29.72	-17.49	-8.59	--
Provision for Tax	-0.84	-0.78	0.43	0.31	0.29	--
Profit after Tax (Net Income)	-30.42	-40.25	-30.15	-17.79	-8.87	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-38.47	-40.25	-30.15	-17.79	-8.87	--

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	8.16	34.16	38.40	14.45	-21.86	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.40	0.50	0.55	0.30	46.21	--
Current Liabilities	5.71	6.47	6.88	5.30	2.77	--
Total Liabilities	19.97	1.39	45.83	20.05	27.13	--

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	1.23	-38.35	1.59	2.36	0.27	--
Current Assets	13.03	39.74	44.24	17.69	26.85	--
Total Assets	19.97	34.66	45.83	20.05	27.13	--
Total Debt*	0.40	--	0.55	0.30	--	--
Net Current Assets	7.33	33.27	37.36	12.39	24.08	--

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-38.36	-27.54	-14.95	-6.37	--
Cash Flow from Investing Activities	--	-0.01	0.18	-1.58	-0.25	--
Cash from Financing Activities	--	33.33	52.92	7.08	25.42	--
Net Cash Inflow / Outflow	--	--	25.56	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-2.08	-2.88	-3.01	-3.56	--	--
Cash EPS ($)	--	-2.86	-3.00	-3.53	--	--
Adjusted Book Value ($)	--	2.44	3.84	2.89	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.74	-2.75	-2.99	--	--
Free Cash Flow per Share ($)	--	-2.74	-2.76	-3.26	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-110.12	-112.27	500.69	--	--
ROE (%)	-184.49	-110.96	-114.08	480.48	--	--
ROA (%)	-85.00	-170.51	-91.52	-75.42	--	--
EBIT Margin (%)	-1,803.17	-1,170.28	-800.03	-739.55	--	--
Net Margin (%)	-1,755.34	-1,148.15	-813.00	-762.30	--	--
Cash Profit Margin (%)	-0.01	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-48.48	-0.05	0.59	--	--	--
EBIT Growth (%)	19.62	-38.31	-71.86	-101.01	--	--
Net Profit Growth (%)	23.19	-33.53	-69.44	-100.52	--	--
EPS Growth (%)	34.10	0.05	0.15	--	--	--
Book Value Growth (%)	-80.66	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-2.96	-3.65	--	--	--
Price / Book Value	1.02	3.49	2.86	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.07	-2.01	-2.32	--	--	--
Close Price ($)	1.00	8.51	11.00	--	--	--
High Price ($)	14.50	28.68	16.50	--	--	--
Low Price ($)	0.70	7.74	8.62	--	--	--
Market Cap ($ Cr)	7.91	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	--	0.01	0.02	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	2.28	6.14	6.43	3.34	9.68	--
Quick Ratio	2.28	--	--	--	--	--
Interest Coverage	-217.30	-157.81	-529.73	-76.72	--	--

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	7.44	--	18.37	20.09	--	--
Asset Turnover	0.05	0.15	0.11	0.10	--	--
Receivable days	--	35.47	56.64	36.70	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	361.50	327.42	550.43	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.